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5AUTOMATIC FILLING EQUIPMENT ALLOWS FOR INCREASE IN MAXIMUM DOSE
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ABSTRACT
 In recent years there has been increasing interest in the 
pulmonary delivery of high dose dry powder drugs, such as antibiotics. 
Drugs in this class need to be dosed in doses far over 2.5 mg, and the 
use of excipients should therefore be minimized. To our knowledge, 
the effect of the automatic filling of high dose drug formulations on 
the maximum dose that can be filled in powder inhalers, and on the 
dispersion behavior of the powder, have not been described so far. 
In this study, we aimed to investigate these effects after filling with 
an Omnidose, a vacuum drum filler. Furthermore, the precision and 
accuracy of the filling process were investigated. Two formulations 
were used—an isoniazid formulation we reported previously and 
an amikacin formulation. Both formulations could be precisely and 
accurately dosed in a vacuum pressure range of 200 to 600 mbar. No 
change in dispersion was seen after automatic filling. Retention was 
decreased, with an optimum vacuum pressure range found from 400 
to 600 mbar. The nominal dose for amikacin was 57 mg, which resulted 
in a fine particle dose of 47.26 ± 1.72 mg. The nominal dose for isoniazid 
could be increased to 150 mg, resulting in a fine particle dose of 107.35 
± 13.52 mg. These findings may contribute to the understanding of the 













 For about 50 years, the pulmonary administration of highly 
potent low dose drugs, in the form of dry powders, has been used to 
treat pulmonary diseases [1]. Dry powder particles in the aerosol for 
inhalation should have a size between 1 and 5 μm to obtain adequate 
lung deposition [2]. This size requirement of the powder negatively 
affects its bulk flow properties [1,3]. To improve the flow properties, and 
with that dose reproducibility, low dose drugs are usually formulated in 
adhesive mixtures, where the drug in question adheres to the surface of 
freely flowing coarse lactose carrier particles [4,5].
 In recent years there has been increasing interest in the pulmonary 
administration of low potency, high dose drugs, such as antibiotics. 
Drugs in this class need to be dosed in doses over 2.5 mg without 
excipients [1]. In reality, most of the drugs in this group need to be dosed 
much higher than that. However, at doses above 2.5 mg, improving the 
flow properties, and thus dose reproducibility, by formulating them in 
adhesive mixtures is no longer feasible because this formulation type 
usually does not contain more than 4% active drug [1].
 The automatic filling of low dose formulations has been 
extensively investigated. Multiple filling techniques exist, such as 
“pepper-shaker” filling, tamp filling, vacuum drum filling, vacuum 
dosator filling, and dosator nozzle filling. However, almost all of them 
are designed to work with free-flowing adhesive mixtures [6–12]. To our 
knowledge there is no literature available that describes the automatic 
filling of high dose drugs which contain no or only minor amounts of 
excipient. As the physicochemical properties of the formulation are not 
masked by lactose carrier particles, automatic dosing in a reproducible 
5.1
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way is a significant challenge. Of course, non-reproducible filling 
results in an inconsistent dose being delivered to the patient, which is 
undesirable. Moreover, it is unknown what the effect of the automatic 
filling on the maximum dose and dispersion behaviors are.
 Not only do the physicochemical properties of the formulation 
have an effect on automatic dosing, automatic dosing may also have an 
effect on the formulation and its performance. Compaction, pelletization, 
or the formation of aggregates may occur by design or as a byproduct 
of automatic filling [6]. This is likely to have an effect on the dispersion 
behavior of the formulation. The poor break up of aggregates may lower 
the fine particle fraction (FPF), whereas, on the other hand, increased 
disintegration forces (e.g., through impaction) may increase the FPF. 
Additionally, powder may be further compacted in the dosing system 
of the inhaler, which lowers powder emission from the inhaler. This 
introduces other causes of inconsistent dose delivery to the patient.
 In this study, the Omnidose powder filling machine is used 
to automatically fill single dose cartridges (SDC) that are used in the 
Twincer® and Cyclops® dry powder inhalers (DPI). The Omnidose 
is a vacuum drum filler [6], where boreholes in a drum are filled with 
powder from a hopper driven by a difference in air pressure, called 
vacuum pressure in this article (Fig. 5.1). In this way, powder plugs or 
pellets are formed with the shape and volume of the boreholes, which 
are then dropped in the SDCs. The density and, therefore, the mass of 












 To determine if the Omnidose can precisely and accurately 
dose high dose drugs, we performed experiments with two spray-dried 
formulations—an amikacin formulation that contains 1% L-leucine 
and an extensively characterized isoniazid formulation that contains 
3% trileucine [13,14]. Both are antibiotics used in the treatment of 
tuberculosis [15]. A substantial amount of SDCs were filled under 
different conditions, after which the uniformity of dosage units was 
calculated. Furthermore, the effect on the dispersion of the powders 
from the Cyclops® DPI was determined and compared to hand-filled 
SDCs.
Figure 5.1 -  A schematic representation of the vacuum drum filler used in this study.
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 MATERIALS AND METHODS
5.2.1 | Materials
 Isoniazid and L-leucine used for this study were purchased from 
Sigma Aldrich (St. Louis, MO, United States). Trileucine was purchased 
from Bachem (Bubendorf, Switzerland). Amikacin was obtained from 
OfiPharma (Ter Apel, The Netherlands).
5.2.2 | Spray-Drying
 Isoniazid and amikacin powders were spray-dried using a B-290 
mini spray-drier, obtained from Büchi (Flawil, Switzerland). To obtain 
enough powder for automatic filling, isoniazid was spray-dried in three 
sessions and amikacin in two. The difference being explained by the fact 
that the process speed of the isoniazid formulation is lower. Isoniazid 
was spray-dried with 3% (w/w) trileucine in demineralized water, with 
an inlet temperature of 40 °C and a feed rate of 1 mL/min. The amikacin 
solutions in demineralized water contained 1% (w/w) L-leucine and 
were spray-dried at 130 °C and 2.5 mL/min. A NE-300 syringe pump, 
obtained from ProSense B.V. (Oosterhout, The Netherlands) was used 
to control the feed rate. Other conditions were kept the same for both 
compounds. The other conditions for the two compounds were an 
atomizing airflow (Qflow) of 50 mm, an aspirator air flow of 100%, and a 
total solute concentration of 50 mg/mL.
5.2.3 | Primary Particle Size Distribution Analysis
 The primary particle size distributions of the produced powders 
were measured by laser diffraction analysis. A HELOS diffraction unit 
equipped with a RODOS dry disperser, both provided by Sympatec 













of approximately 10 mg was placed on the RODOS dry disperser and 
dispersed at 3 bars. An R3 lens was fitted to the diffraction unit, enabling 
it to size particles between 0.1 and 175 μm. Powders were measured in 
triplicate. The average and standard deviation were calculated over six 
measurements after the data of the two duplicate amikacin batches 
were grouped together, or over nine measurements for the three 
isoniazid batches.
5.2.4 | Automatic Filling
 For the automatic filling of the SDCs an Omnidose drum filler 
(Harro Höfliger, Allmersbach im Tal, Germany) was used. For the isoniazid 
and amikacin powders, pellets were made with vacuum pressures of 
200, 400, and 600 mbar. The emptying of the boreholes was done with 
a pressure of 0.5 bars, while the cleaning pressure was set at 1.8 bars. 
Per SDC, 24 pellets were dosed, calculated to result in a dose of around 
55 mg, depending on the compound and the vacuum pressure. A row of 
eight SDCs was filled in approximately 35 s with this nominal dose. For 
isoniazid higher doses were also tested, with nominal doses of 85 and 
105 mg.
 For amikacin, the effect of relative humidity (RH) during filling 
was also tested. A cover plate was made, which sealed the hopper of the 
Omnidose. The hopper was purged with pressurized air that was dried 
by leading it through a column filled with silica beads. Environmental 
conditions during amikacin filling were a temperature between 20.4 and 
22.5 °C and an RH between 34 and 40%.
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5.2.5 | Uniformity of Dosage Units
 To determine the reproducibility of the automatic filling process, 
the uniformity of dosage units was determined according to procedure 
2.9.47—Demonstration of uniformity of dosage units using large sample 
sizes—of the European pharmacopoeia 9.0. Based on the decision table 
in procedure 2.9.40, it was decided that the analysis could be performed 
based on mass variation (MV), as it was deemed that the different 
components after spray-drying have a similar uniform distribution 
through the powder as “solutions freeze-dried in final container”. 
Moreover, the drug content in the powders was far over 25%, with 99% 
for amikacin and 97% for isoniazid.
5.2.6 | Dynamic Vapor Sorption
 Dynamic vapor sorption (DVS) analysis was performed on the 
amikacin formulation using a DVS-1 (Surface Measurement Systems, 
Middlesex, United Kingdom). About 35 mg of sample was used for 
each run. Two different runs were made. Both runs started at 0% RH 
and increased the RH when the mass change per time interval (dm/
dt) was below 0.0005%/min. During the first type of run, the RH was 
increased in steps of 10% to a maximum of 90%, after which the RH 
was decreased back to 0% RH with the same steps. During the second 
type of run the RH was increased to 40% in one step and was decreased 
back to 0% after that.
5.2.7 | Moisture Content Determination
 The moisture content of the amikacin pellets after automatic 
filling was obtained by Karl Fisher titration. An 831 KF Metrohm 
Coulometer (Herisau, Switzerland), equipped with a 728 stirrer, was used 












Coulomat AG, provided by Fluka (Seelze, Germany). Approximately 10 
mg of pellets was dissolved in around 2 mL of Hydranal Coulomat AG, 1 
mL of which was injected into the reaction vessel. The preparation of the 
samples was performed under dry nitrogen gas. Fifteen amikacin SDCs 
filled at 400 mbar were analyzed in duplicate. Five made at the start of 
the automatic filling run, five made at the end of the run, and five made 
at the end of the run under dried air (instead of dry nitrogen). The 400 
mbar runs took approximately 4 h each. Moisture content is expressed 
as a percentage of the total powder mass (% w/w).
5.2.8 | Scanning Electron Microscopy
 Scanning electron microscopy (SEM) images were taken with 
the JSM 6460 SEM, (JEOL, Tokyo, Japan). Samples were fixed to an 
aluminum sample stub by the use of double-sided carbon tape, after 
which 10 nm of gold was sputter-coated by a JFC-1300 auto fine coater, 
also from JEOL. The coater was purged with argon gas. Images were 
taken with a spot size of 25 and an acceleration voltage of 10 kV under 
high vacuum, with a working distance of 10 mm. The secondary electron 
detector was used to construct the images.
5.2.9 | Inhaler Dispersion Analysis
 The dispersion behavior of the powders and the pellets from 
the Cyclops® inhaler was determined with a HELOS diffraction unit 
equipped with an INHALER2000 adaptor (Sympatec, Clausthal-
Zellerfeld, Germany). The diffraction unit was equipped with an R3 lens 
with a measuring range of 0.1 and 175 μm. The dispersion pressures 
tested were 2, 4, and 6 kPa. At each dispersion pressure, the powder 
and the 200, 400, and 600 mbar pellets were measured five times. The 
retention of the powder by the inhaler (i.e., the non-emitted powder 
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mass) was determined gravimetrically. The FPF was calculated as 
a percentage of the emitted dose. The fine particle dose (FPD) was 
calculated by multiplying the FPF with the emitted dose (= FPF × (1 − 
inhaler retention)). For amikacin samples, prior to dispersion analysis 
approximately 20 mg of sweeper lactose in a size fraction of 250 to 315 
μm was added manually to the SDC.
5.2.10 | High-Speed Imaging
 The dispersion of the powders and pellets in the Cyclops® inhaler 
were imaged during the inhaler dispersion analysis with a Phantom 
VEO 310L high-speed camera, supplied by Vision Research (Wayne, 
NJ, USA). The camera was equipped with an AF Zoom-Nikkor 24–85 
mm f/2.8–4D IF lens, (Nikon, Tokyo, Japan). Light was provided by a 
MULTILED QT, supplied by GS Vitec (Bad Soden Salmünster, Germany). 
Images were taken at a rate of 3200 frames per second (fps), with a 
resolution of 1280 × 800 and an exposure time of 200 μs. Afterwards, 
each video was analyzed as follows: frame numbers were determined 
for the occurrence or completion of different events, such as the start 
of the inhaler dispersion analysis, complete emptying of the SDC, 
dispersion of the bulk of the powder, and dispersion of all the powder. 
Dispersion of the bulk was estimated visually when around 95–99% of 
the powder had left the air classifier of the Cyclops®. The difference 
in frame number between the start of the analysis and the three other 
events was determined and divided by 3200. This gives the duration of 
each event in seconds. The average and standard deviation was then 












5.2.11 | Large SDC
 To increase the nominal dose above what could physically fit in 
the standard SDC (350 mm3), an SDC of increased width was tested 
(520 mm3). The larger SDC (L-SDC) is made out of polycarbonate, while 
the standard SDC is made out of low-density polyethylene. The L-SDC 
was hand filled with 400 mbar isoniazid pellets from automatically filled 
standard SDCs to a nominal dose of 150 mg, the maximum that could 
physically fit.
5.2.12 | Drop Test
 To test the effect of the repeated dropping of the inhaler filled 
with either loose powder or pellets, sealed SDCs were placed in a test 
sieve on an AS200 “g” vibratory sieve shaker, provided by Retsch (Haan, 
Germany). SDCs were vibrated at 1.5 g for 30 s, after which inhaler 
performance (dispersion at 2, 4, and 6 kPa) was determined. The tested 
SDCs contained loose powder, or pellets filled at either 400 or 600 mbar 
of isoniazid or amikacin.
5.2.13 | X-ray Diffraction Analysis
 X-ray analysis was performed with a Bruker D2 Phaser (Billerica, 
MA, United States). Samples were scanned in a range of 5 to 60° 2θ 
with steps of 0.004° 2θ, each step taking 1 s. The air scatter screen and 
divergence slit openings were 3 mm and 1 mm, the detector opening 
was 5°. The sample stage was spun at 60 rpm. Two samples were 
measured—an amikacin 1% L-leucine sample stored at 0% RH and an 




 Three isoniazid and two amikacin batches were spray-dried. 
The fraction ≤ 5 μm for the isoniazid batches is 91.80 ± 3.55% and for 
amikacin 87.37 ± 1.35%. The yields were between 86% and 88% for the 
isoniazid batches and between 84% and 86% for the amikacin ones. The 
outlet temperature was approximately 26 °C during the spray-drying of 
isoniazid, and approximately 66 °C during the spray-drying of amikacin.
 In Table 5.1, the results of the uniformity of dosage units test for 
the isoniazid formulation after filling SDCs at different vacuum pressures 
are given. According to the pharmacopeial procedures described in the 
material and methods section, the acceptance value should be ≤ 15. 
As can be seen, at all three vacuum pressures, the acceptance value 
is considerably lower. Furthermore, no out of specification results were 
obtained. Lastly, as expected, the average dose increases with increasing 
vacuum pressure.
Table 5.1 - The results of the uniformity of dosage units test after dosing with the 
Omnidose for the isoniazid with 3% trileucine powder at three different vacuum 
pressures. Acceptance value (criteria ≤ 15) and the amount of dosage units out of 










200 mbar 56 53.53 ± 0.69 1.37 0
400 mbar 223 55.82 ± 0.25 0.55 0













 The results of the uniformity of dosage units tests for the 
amikacin powder are shown in Table 5.2. The SDCs filled at 200 and 
600 mbar vacuum pressures have acceptance values below 15 and zero 
dosage units were out of specification. The 400 mbar pellets, made at 
the end of the day, have two out of specification results, where only one 
is allowed. During this run, sometimes empty or half-filled boreholes 
were observed, as well as aggregates in the powder bed. The 400 mbar 
pellets made under dry air seem more reproducible, with an acceptance 
values below 15 and zero out of specification dosage units. When looking 
at the 200 and 600 mbar pellets, the dosage increases with increasing 
vacuum pressure, as is expected. The 400 mbar pellets produced under 
dry air are made under different humidity conditions and thus cannot be 
directly compared.
Table 5.2 - The results of the uniformity of dosage units tests after dosing with the 
Omnidose for the amikacin with 1% L-leucine powder at three different vacuum 
pressures. Acceptance value (criteria ≤ 15) and the amount of dosage units out of 
specification are determined according to European pharmacopoeia 9.0, procedures 
2.9.40. and 2.9.47. * pellets produced under dry air.
Vacuum 
Pressure






200 mbar 56 52.08 ± 0.75 1.50 0
400 mbar 223 51.81 ± 3.85 8.46 2
400 mbar* 166 57.01 ± 2.05 4.48 0
600 mbar 56 57.05 ± 0.97 1.95 0
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 Amikacin is known to be hygroscopic—the DVS results for the 
amikacin formulation confirms this (Fig. 5.2). The amikacin formulation 
increases 4.81% in mass in the RH step of 0 to 10% RH. At 30% RH, 
just slightly below the RH experienced during automatic filling, the 
mass increased by 9.08%. It is interesting to note that mass increased 
up to 70% RH, after which the mass decreased. This is likely the result 
of moisture-induced crystallization [16]. During this process, powder 
fuses together, which was seen after the DVS measurement. This lowers 
the total surface area, and thus decreases the amount of adsorbed 
moisture. Moisture is likely absorbed in the crystalline structure, 
as the mass hardly decreases during the desorption phase. This is 
corroborated in Figure 5.2B as, when exposed to a maximum of 40% RH, 
no moisture was taken up permanently and no powder fusion was seen. 
The adsorption of moisture by amikacin is fast. When exposed to 40% 
RH, mass increased, by 8.07% in 33 and 44 min for the two duplicates, 
respectively.











































Figure 5.2 - The DVS results for the amikacin formulation— (A) shows the sorption and 
desorption data from 0% to 90% RH and back in steps of 10% RH; (B) shows the data 












 The moisture contents of the automatically filled amikacin SDCs 
are shown in Figure 5.3. As can be seen, the moisture contents hardly 
differ between the start and end of the filling process, or between filling 
during normal and dry air conditions. All three groups fall between 11 
and 11.5% moisture content.
Figure 5.3 - The moisture contents for the amikacin formulation automatically filled 
into SDCs. Start filling samples are the first five SDCs filled under normal conditions. 
End filling samples are the last five SDCs filled under normal conditions. The end filling 
dry air samples are the last five SDCs filled when automatic filling took place under dry 
air (average ± SD, n = 10).
0 5 10 15




 The amikacin formulation after spray-drying displays a folded 
shell morphology, where the shell buckled as a result of internal voids, 
(Fig. 5.4A). This morphology is completely lost after the DVS run to 90% 
RH and one huge aggregate is formed. The surface of this aggregate 
seems to consist of smaller particles fused together, as can be seen in 
Figure 5.4B. When exposed to a maximum of 40% RH, no fusion is seen 
and the folded shell morphology is retained.
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 The X-ray diffraction data, shown in Figure 5.5, show the 
considerable effect of the storage conditions. When stored at 0% RH 
directly after spray-drying the sample is amorphous, evidenced by 
the presence of an amorphous halo and the lack of peaks (black line). 
When stored at 80% RH for one week, peaks are present, showing that 
a crystal structure has formed (blue line).
Figure 5.4 - SEM images of the spray-dried amikacin formulation containing 1% 
L-leucine. (A) shows the powder before DVS measurement. (B) shows the same 
formulation after being exposed to 90% RH and (C) shows the same powder after being 
exposed to 40% RH during the DVS measurements. Magnification 5000×.
Figure 5.5 - The X-ray spectra of the amikacin 1% L-leucine samples. The black line is 
the amikacin sample stored at 0% RH and the blue line is an amikacin sample stored at 












 Figure 5.6 shows the FPFs, the powder mass retained by the 
Cyclops® inhaler, and the FPDs measured during the dispersion of the 
isoniazid formulation in its powder form as well as pellets. As can be seen, 
the FPFs (Fig. 5.6A) do not seem to differ much between the different 
pressure drops or between the different pellets and loose powder. Inhaler 
retention, however, does differ substantially (Fig. 5.6B). Retention seems 
to decrease with increasing pressure drop. Furthermore, at 4 and 6 kPa, 
the 200 mbar pellets have a higher retention than the loose powder and 
the 400 and 600 mbar pellets. At 2 kPa, the 400 and 600 mbar pellets 
have substantially lower retentions than the 200 mbar pellets and loose 
powder. This is reflected in the FPDs (Fig. 5.6C), the 400 and 600 mbar 
pellets seem to result in higher FPDs than the 200 mbar pellets and 
loose powder, with the exception of the loose powder measured at 6 
kPa.
Figure 5.6 - The effect of vacuum pressure on the dispersion from the Cyclops® inhaler 
of 55 mg isoniazid. (A) shows the FPFs for the loose powder and the three different 
pellets, (B) shows the retention, and  (C) shows the FPD (average ± SD, n = 5). The FPD 



































































 In Figure 5.7 the dispersion times for the isoniazid powder and 
pellets are shown. The emptying of the SDC happens almost immediately 
for the powder and all different pellets, with the dose having left the SDC 
under 0.14 s at every condition tested. Bulk and total dose dispersion 
time depend on the pressure drop used, with dispersion being quicker at 
higher pressure drops, which is expected. However, whatever pressure 
drop is used, dispersion is fast. Bulk dispersion varies between 0.5 
and 0.15 s and total dispersion between 0.75 and 0.21 s, depending on 
pressure drop and vacuum pressure.








































Figure 5.7 - The dispersion times for 55 mg isoniazid.  (A) shows the time it took to 
empty the SDC, (B) shows the time it took for the bulk of the powder to be dispersed, 
and (C) shows the time needed to disperse the complete dose (average ± SD, n = 5).
 The inhaler dispersion data for the amikacin loose powder and 
the three different pellets are shown in Figure 5.8. For the 400 mbar 
samples, the pellets made under dry air were used. The effect on the FPF, 
shown in Figure 5.8A, is small. However, retention (Fig. 5.8B) seems to 
be lower for pellets than for the loose powder. This is further illustrated 
in the FPD (Fig. 5.8C), where the dose is somewhat higher for the 400 












 SDC emptying time for the amikacin formulation is similar to 
that of the isoniazid formulation, with the cartridge being emptied within 
0.14 s (Fig. 5.9A). Unlike isoniazid, the pelletization of the amikacin 
formulation substantially increases the bulk and total dispersion times, 
especially at 2 kPa (Fig. 5.9B and C). Additionally, the difference between 
2 kPa and the higher pressure drops is larger, with up to a second of 










































































































Figure 5.8 - The effect of vacuum pressure on the dispersion of 57 mg amikacin. (A) 
shows the FPFs found for the loose powder and three different pellets, (B) shows the 
inhaler powder retention, and (C) shows the FPD (average ± SD, n = 5). The FPD is 
calculated by multiplying the FPF with the emitted dose (= FPF × (1 − retention)).
Figure 5.9 - The dispersion times for 57 mg amikacin.  (A) shows the time it took to 
empty the SDC, (B) shows the time it took for the bulk of the powder to be dispersed, 
and (C) shows the time needed to disperse the complete dose (average ± SD, n = 5).
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 The drop test does not seem to have a substantial effect on the 
FPF generated from isoniazid powder or pellets (Fig. 5.10A). However, 
the powder retention is increased, especially at 2 kPa (Fig. 5.10B). Visual 
observation showed that most pellets were disintegrated after the drop 
test and that the retention predominantly increased in the SDC, where 
the now loose powder was compressed against the wall and cover foil. 
The increase in retention is reflected in the FPD (Fig. 5.10C), drop test 




































































Figure 5.10 - The effect of the drop test on the inhaler dispersion of 55 mg isoniazid. (A) 
shows the FPFs for the powder, and the 400 and 600 mbar pellets before and after the 
drop test. (B) shows the retention for these samples and (C) shows the FPD (average ± 
SD, n = 5). The FPD is calculated by multiplying the FPF with the emitted dose (= FPF × 
(1 − retention)).
 Similar to isoniazid, the FPF generated from the different 
amikacin products is not affected by the drop test (Fig. 5.11A). Also 
for this product the retention is increased by the drop test (Fig. 5.11B). 
However, the increase in retention seems lower than that for the isoniazid 
pellets. Pellets were also not completely disintegrated. This is reflected 
in the FPD (Fig. 5.11C). FPD is lower for the drop test samples, but this 












 The compression of the powder that occurs during the automatic 
filling allowed for an increase in the mass that can be filled into the 
SDCs without decreasing dispersion efficiency. This is interesting 
because it may reduce the number of inhalations that is required for 
the administration of a complete dose. Increasing the nominal dose of 
isoniazid has a negligible effect on the FPF (Fig. 5.12A), with a maximum 
decrease of 4% at 2 kPa with increasing dose. Retention increases 
with increasing dose at 2 kPa (Fig. 5.12B), and decreases slightly with 
increasing nominal dose at 4 and 6 kPa. The FPD increases substantially 
by increasing the nominal dose (Fig. 5.12C). From a FPD of 39.98 ± 2.07 
mg, obtained from a nominal dose of 55 mg at 4 kPa to 69.23 ± 2.62 
mg obtained from a nominal dose of 105 mg. The L-SDC results in a 
comparable FPD with a nominal dose of 105 mg. The maximum nominal 
dose that could fit in the L-SDC was 150 mg. The FPD is increased 
substantially, resulting in an average FPD of 107.35 ± 13.52 mg. It is 
interesting to note that the FPF of 70.90 ± 7.67% for the 150 mg dose is 

































































Figure 5.11 - Effect of the drop test on the dispersion of 57 mg amikacin by the Cyclops®. 
(A) shows the FPF of the different products before and after the drop test, (B) shows 
the retention and (C) shows the FPD (average ± SD, n = 5). The FPD is calculated by 
multiplying the FPF with the emitted dose (= FPF × (1 − retention)).
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 DISCUSSION
 Our results show that isoniazid and amikacin can be precisely 
and accurately dosed with the Omnidose system in a vacuum pressure 
range from 200 to 600 mbar, as shown in Tables 5.1 and 5.2. Powder 
flowability decreases with decreasing particle size, with particles for 
pulmonary administration showing poor flow characteristics [17]. 
However, the poor flowability, expected from the two tested formulations, 
do not seem to result in unreliable dosing.
 Amikacin automatic filling needs to take place under a dry 
environment. As can be seen in Figure 5.2A, amikacin is hygroscopic, 
and between 70% and 80% RH a structural change in the powder was 
found to occur. A similar issue was seen for the isoniazid formulation, 
albeit between 80% and 90% RH [14]. This is likely moisture induced 
crystallization [16]. This is corroborated by the X-ray data (Fig. 5.5). When 
stored at 80% RH, amikacin was crystalline, while it was amorphous 




































































Figure 5.12 - The inhaler dispersion results for three different nominal doses of isoniazid 
pellets produced at 400 mbar. (A) shows the FPFs, (B) shows the inhaler retention and 
(C) shows the FPD (average ± SD, n = 5). The FPD is calculated by multiplying the FPF 
with the emitted dose (= FPF × (1 − retention)). The three different nominal doses used 














amikacin is further corroborated by Figure 5.4, where the morphology 
of the spray-dried powder before and after DVS measurement to 90% 
RH is radically different. Before DVS, a typical folded-shell morphology 
is seen for spray-dried material with L-leucine [18]. After DVS, a sizable 
aggregate is formed, which seems to consist of smaller particles fused 
together, likely a result of crystallization. However, based on Figure 5.2, 
the aggregate is formed between 70% and 80% RH. The automatic 
filling of amikacin took place between 34 and 40% RH. As can be seen in 
Figure 5.4C, no aggregates are formed when the formulation is exposed 
to 40% RH. This makes it unlikely that aggregates are formed during the 
filling process via this mechanism. The adsorption of water during the 
process and, as a result, the formation of capillary forces, which reduces 
powder flowability, might explain the amikacin results. Amikacin adsorbs 
moisture fast enough for this phenomenon to happen during automatic 
filling. However, as can be seen in Figure 5.3, moisture content at the 
start of the run and at the end are the same. Furthermore, the moisture 
content of the pellets produced under dry air are the same as well. While 
it is likely that capillary forces play a role, further research is needed to 
clarify this phenomenon.
 Automatic filling improves the FPD of isoniazid (Figure 5.6). 
Isoniazid pellets made at vacuum pressures of 400 and 600 mbar result 
in lower retentions than the loose powder and 200 mbar pellets. FPF was 
similar, while an increase was expected. An increase in vacuum pressure 
likely increases the tensile strength of the pellets. Tensile strength for 
agglomerates is calculated by the following formula: σ = 15.6 ((ϕ4 × 
W)/d), where σ is the tensile strength, W is the work of cohesion between 
particles, d is the diameter of the particles, and ϕ is the packing fraction 
[19]. The packing fraction describes the density of a single pellet. As can 
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be seen in Table 5.1, the nominal dose increases with higher vacuum 
pressures and an equal number of pellets, meaning that the density, and 
thus the packing fraction, increases. The resulting increase in packing 
fraction increases the tensile strength. This results in harder pellets, 
which are likely subject to stronger pellet-to-wall collision forces in the 
classifier of the Cyclops®, dispersing them more efficiently. However, 
this was not found to be the case. Retention depends on the applied 
vacuum pressure and the nominal dose (Fig. 5.6B and 5.12B). A higher 
vacuum pressure and a higher nominal dose both reduce the retention. 
The effect of the vacuum pressures may be explained by the increased 
tensile strength. As a pellet has a higher tensile strength, it does not 
disintegrate and compact against the SDC walls as easily, where most 
of the retention was observed. The effect of the nominal dose can be 
explained by the fact that, usually, the retention does not increase 
linearly with increasing nominal dose. The absolute amount retained by 
the inhaler is more or less the same, because it is partly determined by 
the surface of the inhaler, but with respect to percentage, this results in 
a decrease.
 Just as for isoniazid, the automatic filling of amikacin improves 
its FPDs (Fig. 5.8). Again, the 400 and 600 mbar pellets seem optimal. 
However, the differences between the loose amikacin powder and the 
pellets is smaller than it was for isoniazid. Amikacin is known to be 
very cohesive and adhesive [20]. It is likely that, as a result of these 
physicochemical properties, spontaneously formed aggregates may 
already occur in loose powder.
 Dropping the inhaler frequently has a substantial impact on the 












retention being seen. Visual inspection of the isoniazid SDCs showed 
that pellets had been largely destroyed and that powder had compacted 
against the sides and back of the SDC. This powder was not entrained in 
the airstream during the measurement, which decreases the FPD being 
delivered by the device. The supposedly higher tensile strength of the 
amikacin pellets may explain its lower retention after dropping than that 
of the isoniazid formulation. While, again, the retention by the SDC was 
increased following the test, pellets were destroyed to a smaller extent 
than for isoniazid. Some loose powder was still compacted against the 
walls of the SDC and not entrained. However, the difference here is less 
substantial than it was for isoniazid. It is important to note that the drop 
test is a worst-case scenario, with the pellets experiencing vibrations, 
which a disposable device is unlikely to experience in real-life use.
 All isoniazid samples are dispersed in a very short time, leaving 
room to increase the nominal dose (Fig. 5.7). At 4 kPa, the bulk of the 
400 and 600 mbar pellets is dispersed in around 0.24 s. The Cyclops® 
inhaler has an airflow rate of 46.2 L/min at 4 kPa, which means that the 
bulk of the powder is dispersed in the first 0.18 L of air. In general, to 
deliver powder deep into the lungs, powder has to be dispersed in the 
first 0.5 to 1.5 L of air [21]. The dispersion of isoniazid is substantially 
quicker and thus higher nominal doses could probably be dispersed 
within the first 0.5 to 1.5 L of air as well—the rationale being that an 
increase in nominal dose usually means an increase in dispersion time. 
Furthermore, as dispersion is so quick, it lowers the chance that the 
classifier of the Cyclops® gets overloaded with powder or pellets, which 
could lower its efficiency (because of a crowding-out effect) and thus 
the FPF. In our previous study with loose powder, higher doses were 
tested as well [14]. Our findings were that a dose of 80 mg was optimal, 
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which resulted in a FPD of 58.00 ± 2.56 mg. A nominal dose of 100 mg 
did not improve the FPD delivered by the Cyclops®. Here, as a result 
of automatic filling, the nominal doses tested were 85 and 105 mg. The 
85 mg SDCs result in a FPD of 59.12 ± 2.87 mg at 4 kPa, similar to our 
previous results (Fig. 5.12). What is unlike our previous results is that, 
with pellets, the nominal dose of 105 mg does increase the FPD to 69.23 
± 2.62 mg. Furthermore, with a dispersion time of 0.27 s the time has 
increased only slightly. Higher nominal doses are thus possible from 
a timing point of view. Nevertheless, a higher nominal dose does not 
physically fit in the SDC. To amend this, an SDC of increased width was 
designed and tested, named the L-SDC. The highest nominal dose that 
could fit in the L-SDC, which is 150 mg, was tested. Bulk dispersion took 
place in the first 0.39 L of air. FPF seems to lower only slightly with this 
increase in nominal dose, while the FPD increases to 107.35 ± 13.52 mg; 
however, the standard deviation is relatively high. During one of the five 
measurements half of the pellets got stuck in the L-SDC for around two 
seconds before emptying as well. This had the effect of gradually feeding 
the classifier of the Cyclops®, improving its efficiency. It might thus be 
of interest to design a SDC which always feeds the classifier gradually, as 
long as the powder is dispersed in the first 0.5 to 1.5 L of air. However, it is 
likely that there is a maximum FPD that can be administered in a single 
inhalation, after which cough and tolerability by the patient will become 
an issue. Future research is necessary to determine this maximum FPD.
 The dispersion time is considerably longer for amikacin (Fig. 
5.9), with the bulk of the 400 mbar pellets being dispersed in 0.72 s and 
the 600 mbar pellets in 1.11 s, meaning that the bulk is dispersed in the 
first 0.6 to 0.9 L of air. As a result, no higher nominal doses were tested. 












strength of the pellets. The classifier requires more time and pellet-to-
wall collisions to completely disperse an amikacin pellet.
 In future studies it might be of interest to determine the 
suitability of other automatic filling techniques for the automatic filling 
of the isoniazid and amikacin formulations, together with their effect on 
dispersibility and inhaler retention.
 CONCLUSIONS
 The isoniazid and amikacin formulations can be precisely 
and accurately dosed with the Omnidose system, with both products 
fulfilling the uniformity of dosage units requirements of the European 
pharmacopoeia. The Cyclops® inhaler dispersed the produced pellets 
effectively, with the optimal vacuum pressure being in the range of 400 
to 600 mbar for both products. The isoniazid pellets were dispersed 
quickly, which gave room for the nominal dose to be increased to 150 mg. 
The amikacin SDCs were kept at 57 mg because of the longer dispersion 
time required for this product. This resulted in maximum FPDs of 
107.35 ± 13.52 mg for isoniazid and 47.26 ± 1.72 mg for amikacin. These 
results may contribute to the development and upscaling of production 
of an amikacin and an isoniazid dry powder product for inhalation. 
Furthermore, these findings may contribute to the understanding of the 
upscaling of high dose dry powder products for inhalation, which use a 
limited amount of excipient on a whole.
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